

Meeting Agenda

Division:	Iowa Medicaid Enterprise (IME) Quality Improvement Organization (QIO)		
Meeting Title:	Medicaid Clinical Advisory Committee (CAC)		
Facilitator:	Bill Jagiello, D.O.		
Location:	GoToWebinar and conference call		
Date:	July 17, 2020	Time:	1:00 p.m. – 4:00 p.m.

Meeting Objectives

The purpose of the Medicaid CAC is to increase the efficiency, quality, and effectiveness of the Medicaid healthcare system. The Medicaid CAC provides a process for physician and other healthcare provider contributions to promote quality of care, member safety, cost-effectiveness, and positive provider relations through discussion about Medicaid benefits and healthcare services.

The Medicaid CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decisions to the Iowa Department of Human Services (DHS) for the Iowa Medicaid program.

Meeting Participants

Name	Organization
Bill Jagiello, DO	IME
Mark Randleman, DO	IME
Dr. Alexandra Hubbell - Family Practice	
Dr. Andrea Silver - Family Practice	
Clarice Blanchard, PA-C - Family Practice/Emergency Medicine	
Dr. Dana Danley - Family Practice	
Dr. Kathy Lange - Family Practice	
Dr. Polly Ferguson - Pediatric Rheumatology	
Dr. Stephen Mandler - Psychiatry	
Sherry Buske, ARNP - Family Practice	
Dr. Dennis Zachary - Family Practice	
Dr. Paul Mulhausen	Iowa Total Care
Dr. Leslie Schechtman	Amerigroup
Tami Lichtenberg	IME
Becky Carter	IME
Jennifer Ober	IME

Cassie Reece	IME
Pam Lester	IME
Tom Arnhart	Ultragenyx
Tom Kelly	Public attendee
Robert Robey	Public attendee
Ashley Svenson	Public attendee
Teri Stolte	IME

Agenda Topics	Responsible Party
Introductions/Announcements- Welcome Dr. Dana Danley, replacement for Dr. Galioto Bureau Chief of LTSS and Medical Policy - Paula Motsinger	Dr. Jagiello
Approval of Minutes from May Meeting-	Dr. Jagiello
New Business- <ol style="list-style-type: none"> 1. IME update 2. Amerigroup update 3. Iowa Total Care update 	Paula Motsinger/Dr. Jagiello Dr. Schechtman Dr. Paul Mulhausen
Public Comment Period	Guests
Criteria Review <ol style="list-style-type: none"> 1. Habilitation Level of Care 2. Children's Mental Health Waiver - Level of Care 3. Gene Expression Profiling for the Management of Breast Cancer 4. Ado-trastuzumab emutansine (Kadcyla) 5. Crysvita (Burosumab) 6. Fluocinolone acetate intravitreal implant (Iluvien & Retisert) 7. Idursulfase (Elaprase) 8. Memantine (Namenda) for Autism Spectrum Disorder (ASD) 9. Oritavancin (Orbactiv) 10. Back-up ventilators 11. Percussors 12. Pneumatic Compression Devices 13. Strollers and Wheelchairs for Safety 14. Imaging for Incidental Lesions 15. Risk Reduction Mastectomy 16. Reduction Mammoplasty/Mastopexy 17. Enteral Products - Supplies 18. Wearable Automatic External Defibrillator - **NEW** 	Dr. Jagiello
Upcoming Meetings Oct. 16, 2020 January 15, 2021	Dr. Jagiello
Adjournment	Dr. Jagiello

Introductions and Announcements:

Dr. Dana Danley will be replacing Dr. Galieto. She has been practicing at Broadlawns Medical Center for the past 15 years in Family Medicine. She also teaches at Des Moines University and the University of Iowa.

Paula Motsinger has transitioned to the Bureau Chief of Medical Policy for the State of Iowa.

Tami Lichtenberg is the interim QIO Operations Director. She joined the QIO 18 months ago as the senior manager. She has been in healthcare for 20 years working in program development, grant writing, policy, and clinical and non-clinical administration. She most recently ran a hospice and in the past and has been involved in a variety of other duties with Federal policy.

Approval of Minutes from May Meeting:

Dr. Ferguson motioned to approve, Dr. Silvers seconded. The motion to approve as written was carried.

New Business:

1. Amerigroup update - Dr. Schechtman: We have seen an increase in outpatient procedure requests from the COVID response.
2. Iowa Total Care update - Dr. Mulhausen: We have also seen a substantial increase in requests for services over the last month. We have not seen an increase given the rise of unemployment.
3. IME update - Dr. Jagiello: We administer telehealth claims. We will evaluate post-pandemic results and determine how to best implement quality assurance measures to continue using telehealth services. We are working to get provider payments out the door for the CARES program and nursing homes that have cared for COVID patients, as well as other providers.

Public Comment Period:

Tom Arnhart, Ultragenyx - FDA approval as of June 18, 2020, for a new indication for Crysvida. This is used in the treatment of hyperphosphatemia and tumor-induced osteomalacia for patients 2 years of age and older. He will send information to Dr. Jagiello.

Criteria Review:

1. Habilitation Level of Care - Jen Ober, minor changes noted. Dr. Randleman motioned to approve, Dr. Hubbell seconded, motion carried.
2. Children's Mental Health Level of Care - Jen Ober, updated language to be consistent with Iowa Administrative Code. The definition of mental health professional has been clarified in the criteria. There was discussion of how the criteria limits those with Autism spectrum disorder from qualifying for the waiver. The criteria originates directly from Iowa Administrative Code and is not able to be revised by this group. Dr. Randleman motioned to approve as revised, Dr. Silvers seconded, motion carried.
3. Gene Expression Profiling for the Management of Breast Cancer - Dr. Jagiello revised the policy. Dr. Mulhausen noted code 81522 is not on the fee schedule. Dr. Jagiello stated the revision has to be approved, and if approved, will be effective September 1, 2020. Dr. Lange motioned to approve as revised, Dr. Ferguson seconded, motion carried.

4. Ado-trastuzumab emutansine (Kadcyla) - Dr. Randleman motioned to approve as is, Dr. Lange seconded, motion carried.
5. Crysvita (Burosumab) - Dr. Ferguson motioned to approve with FDA indications noted, Dr. Zachary seconded, motion carried.
6. Fluocinolone acetate Intravitreal Implant (Iluvien & Retisert) - No changes to policy. Dr. Zachary motioned to approve, Dr. Lange seconded, motion carried.
7. Idursulfase (Elaprase) - No changes to policy. Dr. Zachary motioned to approve, Dr. Ferguson seconded, motion carried.
8. Memantine (Namenda) for Autism Spectrum Disorder (ASD) - Dr. Mandler questioned the efficacy but there are providers that prefer to prescribe this medication. A discussion was held to grandfather in. Dr. Jagiello asked to reconsider this criteria in October. Dr. Randleman motioned to table it, Dr. Lange seconded, motion carried.
9. Oritavancin (Orbactiv) - Dr. Randleman motioned to table so Dr. Jagiello can review utilization and possible retiring of this policy, Dr. Silvers seconded, motion carried.
10. Back-up Ventilators - Dr. Zachary motioned to approve as is, Dr. Ferguson seconded, motion carried.
11. Percussors - Dr. Jagiello recommended to approve as is. Dr. Zachary motioned to approve, Dr. Lange seconded, motion carried.
12. Pneumatic Compression Devices - Revised at the request of IME Program Integrity unit. Medical necessity was revised for programmable and non-programmable devices. Dr. Silvers motioned to approve as changed, Dr. Zachary seconded, motion carried.
13. Strollers and Wheelchairs for Safety - No changes recommended. Clarice Blanchard motioned to approve, Dr. Zachary seconded, motion carried.
14. Imaging for Incidental Lesions - No changes recommended. Dr. Randleman motioned to approve, Dr. Ferguson seconded, motion carried.
15. Risk Reduction Mastectomy - Dr. Zachary motioned to approve as revised, Dr. Lange seconded, motion carried.
16. Reduction Mammoplasty/Mastopexy - Minor change noted. Dr. Zachary motioned to approve, Clarice Blanchard seconded, motion carried.
17. Enteral Products – Supplies - This will be approved without changes as we are unable to meet with the Iowa Department of Public Health at this time to update. Dr. Lange motioned to approve, Dr. Zachary seconded, motion carried.
18. Wearable Automatic External Defibrillator ****NEW**** - Written at the request of IME Program Integrity unit. Dr. Ferguson motioned to approve as revised, Dr. Silvers seconded, motion carried.

Meeting was adjourned. Next meeting scheduled October 16, 2020, will be held remotely.